BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 20679605)

  • 21. Olaparib shows promise in multiple tumor types.
    Cancer Discov; 2013 Jul; 3(7):OF5. PubMed ID: 23847380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
    Rottenberg S; Jaspers JE; Kersbergen A; van der Burg E; Nygren AO; Zander SA; Derksen PW; de Bruin M; Zevenhoven J; Lau A; Boulter R; Cranston A; O'Connor MJ; Martin NM; Borst P; Jonkers J
    Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17079-84. PubMed ID: 18971340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Making the best of PARP inhibitors in ovarian cancer.
    Banerjee S; Kaye SB; Ashworth A
    Nat Rev Clin Oncol; 2010 Sep; 7(9):508-19. PubMed ID: 20700108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The long and winding road.
    DenBrok W; Simmons C; Gelmon KA
    J Clin Oncol; 2015 Jan; 33(3):229-31. PubMed ID: 25452438
    [No Abstract]   [Full Text] [Related]  

  • 25. BRACAnalysis CDx as a companion diagnostic tool for Lynparza.
    Gunderson CC; Moore KN
    Expert Rev Mol Diagn; 2015; 15(9):1111-6. PubMed ID: 26292709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. To BRCA or Not to PALB.
    McNamara MG; Lamarca A; Hubner RA; Valle JW
    J Clin Oncol; 2015 Aug; 33(23):2581-2. PubMed ID: 26124473
    [No Abstract]   [Full Text] [Related]  

  • 27. Targeting the molecular defect in BRCA-deficient tumors for cancer therapy.
    Venkitaraman AR
    Cancer Cell; 2009 Aug; 16(2):89-90. PubMed ID: 19647219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Olaparib effective in four advanced cancers.
    Cancer Discov; 2015 Jan; 5(1):OF3. PubMed ID: 25583815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?
    Bouwman P; Jonkers J
    Clin Cancer Res; 2014 Feb; 20(3):540-7. PubMed ID: 24270682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PARP inhibitors in ovarian cancer: current status and future promise.
    Liu JF; Konstantinopoulos PA; Matulonis UA
    Gynecol Oncol; 2014 May; 133(2):362-9. PubMed ID: 24607283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Olaparib: a promising PARP inhibitor in ovarian cancer therapy.
    Chen Y; Zhang L; Hao Q
    Arch Gynecol Obstet; 2013 Aug; 288(2):367-74. PubMed ID: 23619942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reply to M.G. McNamara et al and M.S. Copur et al.
    Domchek SM; Kaufman B; Friedlander M
    J Clin Oncol; 2015 Aug; 33(23):2583-4. PubMed ID: 26124483
    [No Abstract]   [Full Text] [Related]  

  • 33. Olaparib: first global approval.
    Deeks ED
    Drugs; 2015 Feb; 75(2):231-40. PubMed ID: 25616434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PARP inhibition in BRCA2-mutated prostate cancer.
    Nientiedt C; Tolstov Y; Volckmar AL; Endris V; Bonekamp D; Haberkorn U; Jäger D; Sültmann H; Stenzinger A; Hohenfellner M; Grüllich C; Duensing S
    Ann Oncol; 2017 Jan; 28(1):189-191. PubMed ID: 27687312
    [No Abstract]   [Full Text] [Related]  

  • 35. It's About Time!
    Tempero M
    J Natl Compr Canc Netw; 2020 Feb; 18(2):115. PubMed ID: 32023523
    [No Abstract]   [Full Text] [Related]  

  • 36. On the road to PARPi-platin.
    Bookman MA
    J Natl Cancer Inst; 2014 Jun; 106(6):dju119. PubMed ID: 24842884
    [No Abstract]   [Full Text] [Related]  

  • 37. Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer?
    Kauff ND
    J Clin Oncol; 2008 Jan; 26(1):9-10. PubMed ID: 18165631
    [No Abstract]   [Full Text] [Related]  

  • 38. BRCA-deficient and triple negative breast cancers: is olaparib effective in both subtypes?
    Sahin I; Ararat E; Altundag K
    J BUON; 2011; 16(1):184-5. PubMed ID: 21674877
    [No Abstract]   [Full Text] [Related]  

  • 39. PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers.
    Stebbing J; Ellis P; Tutt A
    Future Oncol; 2010 Apr; 6(4):485-6. PubMed ID: 20373860
    [No Abstract]   [Full Text] [Related]  

  • 40. Magnitude of benefit of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for malignant tumor: A meta-analysis.
    Gu L; Du N; Jin Q; Li S; Xie L; Mo J; Shen Z; Mao D; Ji J; Khadaroo PA; Chen B
    Crit Rev Oncol Hematol; 2020 Mar; 147():102888. PubMed ID: 32018126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.